Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
PF-08046037 joins PF-08046054 in clinical development.
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
RPCAR01 starts a phase 1 study, albeit one sponsored by academics.
Emilta-L continues to show worse efficacy than a rival ADC discontinued by Pfizer.
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
